Novel anti-angiogenic effects of formononetin in human colon cancer cells and tumor xenograft
- PMID: 23023137
- DOI: 10.3892/or.2012.2056
Novel anti-angiogenic effects of formononetin in human colon cancer cells and tumor xenograft
Abstract
Formononetin is a novel herbal isoflavonoid isolated from Astragalus membranaceus, a medicinal plant that possesses antitumorigenic properties. Our previous findings demonstrated that formononetin initiates growth-inhibitory and pro-apoptotic activities in human colon cancer cells. In the present study, we aimed to further examine the potential of formononetin in controlling angiogenesis and tumor cell invasiveness in human colon cancer cells and tumor xenografts. The results showed that formononetin downregulated the expression of the key pro-angiogenic factors, including vascular endothelial growth factor (VEGF) and matrix metalloproteinases. We also discovered that the invasiveness of metastatic colon cancer cells was alleviated following drug treatment. The potential anti-angiogenic effect of formononetin was examined in nude mouse xenografts. The tumor size and the number of proliferating cells were reduced in the tumor tissues obtained from the formononetin-treated group. The serum VEGF level was also reduced in the drug-treated animals when compared to the controls. These findings suggest that formononetin inhibits angiogenesis and tumor cell invasion, and thus support its use in the treatment of advanced and metastatic colon cancers.
Similar articles
-
Astragalus saponins modulate cell invasiveness and angiogenesis in human gastric adenocarcinoma cells.J Ethnopharmacol. 2012 Jun 1;141(2):635-41. doi: 10.1016/j.jep.2011.08.010. Epub 2011 Aug 12. J Ethnopharmacol. 2012. PMID: 21864667
-
Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.Cancer Sci. 2008 Oct;99(10):2083-96. doi: 10.1111/j.1349-7006.2008.00948.x. Cancer Sci. 2008. PMID: 19016770
-
Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.Cancer Chemother Pharmacol. 2012 Sep;70(3):425-37. doi: 10.1007/s00280-012-1923-x. Epub 2012 Jul 20. Cancer Chemother Pharmacol. 2012. PMID: 22814678
-
Potential Anticancer Properties and Mechanisms of Action of Formononetin.Biomed Res Int. 2019 Jul 28;2019:5854315. doi: 10.1155/2019/5854315. eCollection 2019. Biomed Res Int. 2019. PMID: 31467899 Free PMC article. Review.
-
VEGF and colon cancer growth beyond angiogenesis: does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism?Curr Pharm Des. 2014;20(7):1041-4. doi: 10.2174/1381612819999131218175905. Curr Pharm Des. 2014. PMID: 23755727 Review.
Cited by
-
Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review.Cancer Metastasis Rev. 2023 Oct 4. doi: 10.1007/s10555-023-10136-9. Online ahead of print. Cancer Metastasis Rev. 2023. PMID: 37792223 Review.
-
Potential Therapeutic Targets of Formononetin, a Type of Methoxylated Isoflavone, and Its Role in Cancer Therapy through the Modulation of Signal Transduction Pathways.Int J Mol Sci. 2023 Jun 3;24(11):9719. doi: 10.3390/ijms24119719. Int J Mol Sci. 2023. PMID: 37298670 Free PMC article. Review.
-
Phenolic Phytochemicals for Prevention and Treatment of Colorectal Cancer: A Critical Evaluation of In Vivo Studies.Cancers (Basel). 2023 Feb 3;15(3):993. doi: 10.3390/cancers15030993. Cancers (Basel). 2023. PMID: 36765950 Free PMC article. Review.
-
Uncovering the effects and molecular mechanism of Astragalus membranaceus (Fisch.) Bunge and its bioactive ingredients formononetin and calycosin against colon cancer: An integrated approach based on network pharmacology analysis coupled with experimental validation and molecular docking.Front Pharmacol. 2023 Jan 23;14:1111912. doi: 10.3389/fphar.2023.1111912. eCollection 2023. Front Pharmacol. 2023. PMID: 36755950 Free PMC article.
-
Identification of key pharmacological components and targets for Aidi injection in the treatment of pancreatic cancer by UPLC-MS, network pharmacology, and in vivo experiments.Chin Med. 2023 Jan 14;18(1):7. doi: 10.1186/s13020-023-00710-2. Chin Med. 2023. PMID: 36641437 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
